Drug Price Cuts in Top Five Countries of Europe - TougherReference Pricing Environment and Drug Price Freeze through2013 E...
that affect the reimbursements of drugs such as positive and negative lists, cost sharing, referencepricing, risk-sharing ...
3.5 Estimated Costs Paid by the Patient and Health Insurance System in the Total ReimbursedPharmacy Market Value at Retail...
6.3.5 Drug Pricing Authority and Procedures 486.3.6 Key Trends in Pricing of Drugs and Cuts 486.3.7 Current Challenges and...
Table 7: Drug Price Cuts in Top Five Countries of Europe, France, Types of Treatment andReimbursement Levels, France, 2011...
Figure 18: Drug Price Cuts in Top Five Countries of Europe, The Public Expenditure on Health asa Percentage of Total Expen...
Upcoming SlideShare
Loading in …5
×

Drug+Price+Cuts+in+Top+Five+Countries+of+Europe+-+Tougher+Reference+Pricing+Environment+and+Drug+Price+Freeze+through+2013+Expected+to+Drive+Down+Healthcare+Costs

218 views
200 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
218
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Drug+Price+Cuts+in+Top+Five+Countries+of+Europe+-+Tougher+Reference+Pricing+Environment+and+Drug+Price+Freeze+through+2013+Expected+to+Drive+Down+Healthcare+Costs

  1. 1. Drug Price Cuts in Top Five Countries of Europe - TougherReference Pricing Environment and Drug Price Freeze through2013 Expected to Drive Down Healthcare CostsReport Details:Published:May 2012No. of Pages: 66Price: Single User License – US$3500Corporate User License – US$10500Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment andDrug Price Freeze through 2013 Expected to Drive Down Healthcare CostsSummaryGBI Research, the leading business intelligence provider, has released its latest research “DrugPrice Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and DrugPrice Freeze through 2013 Expected to Drive Down Healthcare Costs”. It provides acomprehensive overview of the healthcare systems as well as pricing in five European nationswith a detailed analysis of the different regulatory mechanisms used in these countries. The reportclosely scrutinizes major changes in pricing for pharmaceuticals in these European nations in therecent past and their impact in the near future. The countries analyzed in the report are the UK,Germany, France, Spain and Italy.GBI Research’s analysis describes healthcare across the Five European nations, which is largelypublicly financed and is provided by health insurance systems; hence, the European governmentsplay a key role in providing healthcare for their citizens. Health is of high priority for Europe’scitizens and pharmaceutical costs are the third most important component in the member states’healthcare budgets. Currently, the governments of the member countries face substantially risingcosts for the provision of health care (average costs are rising at a faster rate than GDP) due toover-prescription of drugs, their irrational usage, and other key factors such as Europe’s ageingpopulation and increasing cost of new medical technologies. Consumer preference for brandeddrugs to generic drugs in cases where the patent for the drug has expired is also one of thereasons for increasing healthcare costs. Austerity packages announced by the countries areincorporating demand side and supply side policies to reduce the fiscal burden of which healthcarecosts command a major proportion. The governmental demand side policies include measures
  2. 2. that affect the reimbursements of drugs such as positive and negative lists, cost sharing, referencepricing, risk-sharing contracts, tenders, pay-back arrangements and other provisions aimed at amore rational use of pharmaceutical products and making demand more price sensitive. The mostapplied supply policy is price regulation which includes price control and price negotiation. Thespecific features of individual policies vary significantly across the member states. Single pricingmechanism is still an issue in the Europe.Scope- Overview of the macroeconomic factors (PEST analysis of pharmaceutical industry) for top fivecountries of Europe.- Detailed study of the healthcare systems and roles of the key players in the respectivepharmaceutical systems of top five countries of Europe – the UK, France, Germany, Italy andSpain;.- Analysis of the major pricing mechanisms in each country.- Key trends that follow from the recent changes brought about in the pricing of drugs.- Build an understanding of the possible major challenges brought about by the enactment ofchanges in drug price cuts in the countries covered.Reasons to buy- Build understanding of the pharmaceuticals related key pricing mechanisms in top five countriesof Europe.- Optimize your investment through identification and understanding of the changes in thepharmaceuticals regulatory mechanism in the economies.- Develop effective business strategies related to new drug launches through the analytical insightgained from key trends in pricing mechanism scene for the countries covered.Get your copy of this report @http://www.reportsnreports.com/reports/144404-drug-price-cuts-in-top-five-countries-of-europe-tougher-reference-pricing-environment-and-drug-price-freeze-through-2013-expected-to-drive-down-healthcare-costs.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Introduction 93 Drug Price Cuts in Top Five Countries of Europe - Economic Overview 103.1 Healthcare Expenditure as a Percentage of GDP by Country 103.2 Health Expenditure Per Capita With Respect to GDP Per Capita 113.3 Pharmaceutical Expenditure Per Capita with Respect to GDP Per Capita 123.4 Pharmaceutical Expenditure as a Percentage of Healthcare Expenditure 13
  3. 3. 3.5 Estimated Costs Paid by the Patient and Health Insurance System in the Total ReimbursedPharmacy Market Value at Retail Prices 144 Drug Price Cuts in Top Five Countries of Europe – Introductory Concepts 154.1 Industry Analysis 154.1.1 PEST Analysis of European Pharmaceutical Industry 154.1.2 Porters Five Forces Analysis 194.2 Role of Pharmacoeconomics in Pricing 204.3 Pricing Models 214.3.1 External Price Referencing or Internal Price Referencing 214.3.2 Internal Reference Pricing 214.3.3 Price Capping Regulations for Generic Pharmaceuticals 214.3.4 Use of Positive and Negative Formulary 214.3.5 Value-Based Pricing and Risk-Sharing Models 224.3.6 Tendering 234.3.7 VAT Rates for Outpatient Prescription Medicines 244.3.8 Regulatory Mechanisms in Top Five Countries of Europe 255 Drug Price Cuts in Top Five Countries of Europe - Recent Developments in Pricing of Drugs 275.1 EU Single Pricing 275.2 Parallel Trade Impact on Pricing 276 Drug Price Cuts in Top Five Countries of Europe – Geographical Landscape 286.1 The UK 286.1.1 Macroeconomic Factors (PEST Analysis) 286.1.2 Healthcare System in Country 296.1.3 Total Expenditure on Health as a % of GDP 296.1.4 Public Expenditure on Health, % Total Expenditure on Health 306.1.5 Drug Pricing Authority and Procedures 306.1.6 Key Trends in Pricing of Drugs and Cuts 326.1.7 Major Challenges 346.2 France 356.2.1 Macroeconomic Factors (PEST Analysis) 356.2.2 Healthcare System in Country 366.2.3 Total Expenditure on Health as a % of GDP 386.2.4 Public Expenditure on Health, Percentage of Total Expenditure on Health 396.2.5 Drug Pricing Authority and Procedures 406.2.6 Key Trends in Pricing of Drugs and Cuts 426.2.7 Major Challenges 446.3 Germany 446.3.1 Macroeconomic Factors (PEST Analysis) 446.3.2 Healthcare System in Country 456.3.3 Total Expenditure on Health as a Percentage of GDP 466.3.4 Public Expenditure on Health, Percentage Total Expenditure on Health 47
  4. 4. 6.3.5 Drug Pricing Authority and Procedures 486.3.6 Key Trends in Pricing of Drugs and Cuts 486.3.7 Current Challenges and Future Developments 506.4 Spain 516.4.1 Macroeconomic Factors (PEST Analysis) 516.4.2 Healthcare System in Spain 516.4.3 Total Expenditure on Health as a Percentage of GDP 526.4.4 Public Expenditure on Health, Percentage of Total Expenditure on Health 536.4.5 Drug Pricing Authority and Procedures 536.4.6 Key Trends in Pricing of Drugs and Cuts 546.4.7 Current Challenges and Future Developments 556.5 Italy 556.5.1 Macroeconomic Factors (PEST Analysis) 556.5.2 Healthcare System in Country 566.5.3 Total Expenditure on Health as a Percentage of GDP 576.5.4 Public Expenditure on Health, Percentage of Total Expenditure on Health 586.5.5 Drug pricing authority and procedures 586.5.6 Key Trends in Pricing of Drugs and Cuts 596.5.7 Current Challenges and Future Developments 617 Drug Price Cuts in Top Five Countries of Europe - Appendix 627.1 Market Definitions 627.2 Abbreviations 627.3 Sources 647.4 Research Methodology 657.4.1 Macroeconomic Factors (PEST Analysis) 657.4.2 Healthcare Systems 657.4.3 Key Trends in Pricing of Drugs and Cuts 657.4.4 Current Challenges and Future Developments 667.5 Contact Us 667.6 Disclaimer 661.1 List of TablesTable 1: Pricing and Reimbursement in Europe, Supply-Side Pharmaceutical Regulations 16Table 2: Pricing and Reimbursement in Europe, Demand-Side Pharmaceutical Regulations 17Table 3: Drug Price Cuts in Top Five Countries of Europe, Average Time Delay Between ApprovalAnd Market Access, (Days), 2001 - 2005 18Table 4: Drug Price Cuts in Top Five Countries of Europe, Tax Rate, (%), 2011 24Table 5: Pricing and Reimbursement in Europe, Regulatory Mechanisms in Top Five Countries ofEurope 25Table 6: Pricing and Reimbursement in Europe, General Price Changes (%), The UK, 2009-201333
  5. 5. Table 7: Drug Price Cuts in Top Five Countries of Europe, France, Types of Treatment andReimbursement Levels, France, 2011 37Table 8: Drug Price Cuts in Top Five Countries of Europe, France, Social Security Deficit, €bn and$bn, France, 2009-2011 41Table 9: Drug Price Cuts in Top Five Countries of Europe, National Target for Expenditure inPublic Healthcare/ONDAM, France, €bn and $bn, 2010-2011 41Table 10: Drug Price Cuts in Top Five Countries of Europe, List of Innovative Drugs for Regions,AIFA, Italy, 2010 601.2 List of FiguresFigure 1: Drug Price Cuts in Top Five Countries of Europe, Health Expenditure Per Capita WithRespect to GDP per capita, $PPP, 2008 10Figure 2: Drug Price Cuts in Top Five Countries of Europe, Pharmaceutical Expenditure PerCapita and GDP Per Capita ($PPP), 2008 11Figure 3: Drug Price Cuts in Top Five Countries of Europe, Pharmaceutical Expenditure PerCapita with Respect to GDP Per Capita ($PPP), 2008 12Figure 4: Drug Price Cuts in Top Five Countries of Europe, Pharmaceutical Expenditure as aPercentage of Healthcare Expenditure, 2007 – 2009 13Figure 5: Drug Price cuts in Top Five Countries of Europe, Estimated Costs Paid by the Patientand Health Insurance System in the Total Reimbursed Pharmacy Market Value at Retail Prices(%), 2008 14Figure 6: Drug Price Cuts in Top Five Countries of Europe, PEST Analysis, Europe, 2011 15Figure 7: Drug Price Cuts in Top Five Countries of Europe, Porters Five Force Model, 2011 19Figure 8: Pricing and Reimbursement in Europe, ISPOR 33 Guidelines for PharmacoeconomicsAssessment 20Figure 9: Drug Price Cuts in Top Five Countries of Europe, Value-based pricing – Concept andProcess 22Figure 10: Drug Price Cuts in Top Five Countries of Europe, PEST Analysis, The UK, 2011 28Figure 11: Drug Price Cuts in Top Five Countries of Europe, Total Expenditure on Health as a %of GDP, The UK, (%), 2000- 2009 29Figure 12: Drug Price Cuts in Top Five Countries of Europe, Public Expenditure on Health, as a %of total Expenditure on Health, The UK, 2000- 2009 30Figure 13: Drug Price Cuts in Top Five Countries of Europe, NHS expenditure on medicines ($bn)Vs NHS Medicines Cost per capita ($),The UK, 2000-2009 31Figure 14: Drug Price Cuts in Top Five Countries of Europe, PEST Analysis, France, 2011 35Figure 15: Drug Price Cuts in Top Five Countries of Europe, European Counties, The US, Japan,Total healthcare expenditure Vs out-of-pocket expenditure in European Countries, 2008 36Figure 16: Drug Price Cuts in Top Five Countries of Europe, Pharmaceutical Expenditure PerCapita Among the Highest in France, $PPP, 2007-2008 37Figure 17: Drug Price Cuts in Top Five Countries of Europe, Expenditure on Health as aPercentage of GDP, France, (%), 2000- 2009 38
  6. 6. Figure 18: Drug Price Cuts in Top Five Countries of Europe, The Public Expenditure on Health asa Percentage of Total Expenditure on Health, France, 2000- 2009 39Figure 19: Drug Price Cuts in Top Five Countries of Europe, LFSS, France, 2011 40Figure 20: Drug Price Cuts in Top Five Countries of Europe, PEST Analysis, Germany, 2011 44Figure 21: Drug Price Cuts in Top Five Countries of Europe, Germany, Healthcare expenditure, $per inhabitant, Germany, 2008 45Figure 22: Drug Price Cuts in Top Five Countries of Europe, Total Expenditure on Health asPercentage of GDP, Germany, (%), 2000- 2009 46Figure 23: Drug Price Cuts in Top Five Countries of Europe, Public Expenditure on Health asPercentage of Total Expenditure on Health, Germany, 2000-2009 47Figure 24: Drug Price Cuts in Top Five Countries of Europe, Cost Containment Measures,Germany, 1980-2011 48Figure 25: Drug Price Cuts in Top Five Countries of Europe, Structural Reforms by AMNOG,Germany, 2011 49Figure 26: Drug Price Cuts in Top Five Countries of Europe, PEST Analysis, Spain, 2011 51Figure 27: Drug Price Cuts in Top Five Countries of Europe, Total Expenditure on Health as aPercentage of GDP, Spain, (%), 2000-2009 52Figure 28: Drug Price Cuts in Top Five Countries of Europe, Public Expenditure on Health asPercentage of Total Expenditure on Health, Spain, (%), 2000- 2009 53Figure 29: Drug Price Cuts in Top Five Countries of Europe, PEST Analysis, Italy, 2011 55Figure 30: Drug Price Cuts in Top Five Countries of Europe, Total Expenditure on Health asPercentage of GDP, Italy, (%), 2000- 2009 57Figure 31: Drug Price Cuts in Top Five Countries of Europe, Public Expenditure on Health as aPercentage of Total Expenditure on Health, Italy, (%), 2000-2009 58Contact: sales@reportsandreports.com for more information.

×